MedTrace Logo

Intravitreal Triamcinolone and Biomarkers in Rhegmatogenous Retinal Detachment

NCT07774182 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-08-19

No results posted yet for this study

Summary

This prospective, randomized, controlled clinical study evaluates the effects of preoperative intravitreal triamcinolone acetonide (TA) on growth factors and inflammatory mediators in patients with rhegmatogenous retinal detachment (RRD) and proliferative vitreoretinopathy (PVR). Participants are assigned to either an intervention group receiving a 2-mg intravitreal injection of TA 5-7 days before vitrectomy or a control group receiving standard surgical treatment. The study evaluates TGF-β2, TGF-β3, MMP-2, and MMP-9 levels in aqueous humor and vitreous, macrophage cell counts and inflammatory activity in vitreous, subretinal fluid optical density assessed by optical coherence tomography, and vessel diameter index assessed by optical coherence tomography angiography after surgery.

Conditions

  • Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment

Interventions

PROCEDURE

Standard Vitrectomy

Participants underwent standard surgical treatment for rhegmatogenous retinal detachment with proliferative vitreoretinopathy without preoperative intravitreal triamcinolone acetonide.

DRUG

Triamcinolone acetonide (TA)

Triamcinolone acetonide 2 mg was administered by intravitreal injection 5-7 days before vitrectomy.

Sponsors & Collaborators

  • Anggun Rama Yudantha

    lead OTHER

Principal Investigators

  • Anggun Rama Yudantha, Sp.M(K) · Cipto Mangunkusumo Hospital / Faculty of Medicine, Universitas Indonesia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-06
Primary Completion
2026-02-18
Completion
2026-03-18

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07774182 on ClinicalTrials.gov